Cell Therapy Blog – blogspot.com

Despite us both living in the Vancouver area and both being involved in cell therapy, I didn't meet David Hall until we were both in La Jolla late last year for the Alliance for Regenerative Medicine's Stem Cell on the Mesa meeting. Since then we've been keeping in close contact and I have had opportunity to learn a lot more about him,his team,RepliCel, and the company's technology.

David presents a sound logic for the transitions through which he has taken the company in the past 18 months and the pace of that change. He does, perhaps more than many CEO's I have had the opportunity to interview, present a strong and focused vision for the company with a clear goal and a well-defined pathway for how he intends to get the company there. From my vantage point, this vision permeates into most aspects of the company from clinical trial design, to patent strategy, to defining collaborations, and even recruiting.

Suffice it to say I have been increasingly impressed by what I see and welcome the opportunity to share the interview below with you. I hope you enjoy learning a little more about RepliCel as much as I have.

CTB: Tell us a little about your background, David, and how you got involved in a cell therapy company?

DH: My initial career was in finance working on both sides of the street as a money manager and as a banker and analyst. It was as a banker that I came to join ID Biomedical which then led to my joining Angiotech Pharmaceuticals not long after it was started. During my time there I served as Chief Financial Officer, Chief Compliance Officer and Treasurer and Corporate Secretary. After 20 years in life sciences, I spent time focused on public policy in BC and Canada as it related to developing our BC life sciences industry. During that time I was approached to look at a cell therapy company developing a treatment for pattern baldness. Despite my lack of empathy at that time for pattern baldness as a disease, I was struck by the elegance of this groups scientific approach and how that might be expanded into other treatments where there was a deficit of healthy active cells.

CTB:Can you give us a snapshot of RepliCel as a company?

The second is in treating pattern baldness where there is a deficit of dermal sheath cup cells that are responsible for maintaining a hair follicle cycle of fiber production.

CTB:What is the companys technology?

The supporting manufacturing technology is also a critical asset to the company as we believe our process is scalable.

CTB:Where are you doing your trials? Why Europe and Canada?

View post:
Cell Therapy Blog - blogspot.com